查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1628123

冠状动脉支架市场机会、成长动力、产业趋势分析与预测 2025 - 2034

Coronary Stents Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年，全球冠状动脉支架市场估值为 75 亿美元，预计 2025 年至 2034 年复合年增长率为 7.2%。人们越来越偏爱微创治疗。此外，人口老化和日益严重的健康问题也大大促进了市场的扩张。

冠状动脉支架是透过保持狭窄或阻塞的动脉畅通来维持血流的重要装置，在治疗冠状动脉疾病 (CAD) 方面发挥着至关重要的作用。对这些设备的需求不断增长源于不健康的生活方式、人口老化以及心血管疾病发病率的上升。生物可吸收支架、药物洗脱支架 (DES) 和无聚合物支架等创新开发可透过降低动脉再狭窄和血栓相关的风险来提高治疗效果。

市面上依产品分为生物可吸收血管支架（BVS）、药物洗脱支架及裸金属支架。药物洗脱支架在 2024 年占据市场主导地位，因其卓越的预防再狭窄能力而产生了可观的收入。这些支架会释放药物来抑制组织生长，减少重复手术的需要并改善患者的长期治疗效果。

市场范围
开始年份 2024年
预测年份 2025-2034
起始值 75 亿美元
预测值 148 亿美元
复合年增长率 7.2%

从类型来看，市场包括球囊扩张式支架和自扩张式支架。 2024年球囊扩张支架占最大市场份额，占58.3%。它们在部署过程中的精确性和控制性使其对于治疗复杂或狭窄的动脉病例非常有效。这些支架特别有利于解决钙化病灶和硬化斑块，进一步提高其采用率。

依材料划分，市场分为钴铬合金、不锈钢等。钴铬合金支架在2024年占据领先地位，预计到预测期结束时将达到76亿美元。这种材料具有卓越的强度和耐用性，可实现更薄、更有效的设计，从而减少动脉损伤并改善血流。

最终用途细分重点关注心臟中心、医院和门诊手术中心，其中心臟中心将在 2024 年引领市场。

2024 年，北美地区以 30 亿美元的收入引领市场。强大的医疗保健系统、广泛的先进心臟护理服务以及较高的心血管疾病发病率支撑了该地区强大的市场地位。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 冠状动脉疾病负担增加
      • 微创手术的需求不断增加
      • 发展中经济体的技术进步
      • 提高对预防性心臟护理的认识和关注
    • 产业陷阱与挑战
      • 产品故障和召回
      • 严格的监管审批
      • 发展中经济体缺乏熟练的医疗保健专业人员
  • 成长潜力分析
  • 技术景观
  • 未来市场趋势
  • 监管环境
  • 报销场景
  • 差距分析
  • 定价分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2034 年

  • 主要趋势
  • 药物洗脱支架
  • 生物可吸收血管支架（BVS）
  • 裸金属支架

第 6 章：市场估计与预测：按类型，2021 - 2034 年

  • 主要趋势
  • 球囊一次性支架
  • 自费式支架

第 7 章：市场估计与预测：按材料划分，2021 - 2034 年

  • 主要趋势
  • 钴铬合金
  • 不銹钢
  • 其他材料

第 8 章：市场估计与预测：按最终用途，2021 - 2034 年

  • 主要趋势
  • 心臟中心
  • 医院
  • 门诊手术中心
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • Andramed GmbH
  • B. Braun Melsungen
  • Biosensors International Group
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical
  • Elixir Medical Corporation
  • GENOSS
  • Medtronic
  • Meril Life Science
  • MicroPort Scientific Corporation
  • Sahajanand Laser Technology
  • Stryker Corporation
  • Terumo Corporation
简介目录
Product Code: 2966

The Global Coronary Stents Market was valued at USD 7.5 billion in 2024 and is projected to grow at a CAGR of 7.2% from 2025 to 2034. This growth is driven by factors such as the increasing prevalence of cardiovascular diseases, advancements in stent technologies, and a growing preference for minimally invasive treatments. In addition, the aging population and rising health concerns contribute significantly to market expansion.

Coronary stents are vital devices used to maintain blood flow by keeping narrowed or blocked arteries open, playing a crucial role in managing coronary artery disease (CAD). The growing demand for these devices stems from unhealthy lifestyles, aging populations, and the rising incidence of cardiovascular conditions. Innovative developments like bioresorbable scaffolds, drug-eluting stents (DES), and polymer-free stents are enhancing treatment outcomes by reducing risks associated with artery re-narrowing and blood clots.

The market is segmented by product into bioresorbable vascular scaffolds (BVS), drug-eluting stents, and bare-metal stents. Drug-eluting stents dominated the market in 2024, generating significant revenue due to their superior ability to prevent restenosis. These stents release medication to inhibit tissue growth, reducing the need for repeat procedures and improving long-term patient outcomes.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$7.5 Billion
Forecast Value$14.8 Billion
CAGR7.2%

In terms of type, the market includes balloon-expandable and self-expandable stents. Balloon-expandable stents captured the largest market share in 2024, accounting for 58.3%. Their precision and control during deployment make them highly effective for treating complex or narrow artery cases. These stents are particularly beneficial for addressing calcified lesions and hardened plaque, further enhancing their adoption.

By material, the market is segmented into cobalt-chromium alloy, stainless steel, and others. Stents made of cobalt-chromium alloy held the leading position in 2024 and are expected to reach USD 7.6 billion by the end of the forecast period. This material offers exceptional strength and durability, allowing for thinner, more effective designs that reduce artery injuries and improve blood flow.

End-use segmentation highlights cardiac centers, hospitals, and ambulatory surgical centers, with cardiac centers leading the market in 2024. These facilities offer advanced technologies and specialized expertise, ensuring high-quality care for complex cardiac procedures.

North America led the market in 2024, with revenues of USD 3 billion. A robust healthcare system, widespread access to advanced cardiac care, and high rates of cardiovascular disease support the region's strong market position.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising burden of coronary artery disease
      • 3.2.1.2 Increasing demand for minimally invasive procedures
      • 3.2.1.3 Technological advancement in developing economies
      • 3.2.1.4 Increasing awareness and focus on preventive cardiac care
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Product failure and recall
      • 3.2.2.2 Stringent regulatory approvals
      • 3.2.2.3 Dearth of skilled healthcare professional in developing economies
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Future market trends
  • 3.6 Regulatory landscape
  • 3.7 Reimbursement scenario
  • 3.8 Gap analysis
  • 3.9 Pricing analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Drug-eluting stent
  • 5.3 Bioresorbable vascular scaffold (BVS)
  • 5.4 Bare metal stent

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Balloon expendable stent
  • 6.3 Self-expendable stent

Chapter 7 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cobalt-chromium alloy
  • 7.3 Stainless steel
  • 7.4 Other materials

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Cardiac centers
  • 8.3 Hospitals
  • 8.4 Ambulatory surgical centers
  • 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Andramed GmbH
  • 10.3 B. Braun Melsungen
  • 10.4 Biosensors International Group
  • 10.5 Biotronik SE & Co. KG
  • 10.6 Boston Scientific Corporation
  • 10.7 Cook Medical
  • 10.8 Elixir Medical Corporation
  • 10.9 GENOSS
  • 10.10 Medtronic
  • 10.11 Meril Life Science
  • 10.12 MicroPort Scientific Corporation
  • 10.13 Sahajanand Laser Technology
  • 10.14 Stryker Corporation
  • 10.15 Terumo Corporation